Smarter Molecular Strategies for Infectious Disease Trials: Turning Complex Data into Clinical Advantage

Turning complex molecular data into clinical advantage

As infectious disease programs face increasing pressure to generate high-quality data faster, integrated molecular approaches are becoming essential to early-phase success. This webinar explores how hVIVO combines next-generation sequencing (NGS), droplet digital PCR (ddPCR), and 3′ RNA-seq (QuantSeq) to support more precise pathogen detection, resistance monitoring, and host-response biomarker discovery.

Through real-world workflows, attendees will gain practical insight into ddPCR-based pathogen identification, influenza whole-genome sequencing for variant and resistance tracking, and high-throughput transcriptomic profiling to characterize host response. The session will demonstrate how these complementary platforms work together within hVIVO’s clinical and laboratory ecosystem to accelerate infectious disease research and antiviral development.

Key Takeaways Will Include:

• How integrated ddPCR, NGS, and RNA-seq workflows enhance data quality in infectious disease studies
• Practical applications for pathogen quantification, resistance surveillance, and host-response biomarker discovery
• Operational considerations for implementing advanced molecular strategies in early-phase clinical programs
• Where these technologies can most effectively support challenge studies and antiviral development timelines

Speaker Details

Chris Forsdyke

Head Laboratory Services, hVIVO

Read bio

Martin Larke

Principal NGS Biostatistician, hVIVO

Read bio

Chelsea Pratt

Biopharma Segment Marketing Manager, Bio-Rad Laboratories

Read bio

Francesca Manni

Territory Account Manager, Illumina

Read bio